- Home
- FXNC vs CRDF Comparison
FXNC vs CRDF Comparison
Compare FXNC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FXNC
- CRDF
- Stock Information
- Founded
- FXNC 1907
- CRDF 1999
- Country
- FXNC United States
- CRDF United States
- Employees
- FXNC N/A
- CRDF N/A
- Industry
- FXNC Major Banks
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FXNC Finance
- CRDF Health Care
- Exchange
- FXNC Nasdaq
- CRDF Nasdaq
- Market Cap
- FXNC 203.6M
- CRDF 240.2M
- IPO Year
- FXNC N/A
- CRDF N/A
- Fundamental
- Price
- FXNC $25.16
- CRDF $4.24
- Analyst Decision
- FXNC Strong Buy
- CRDF Strong Buy
- Analyst Count
- FXNC 1
- CRDF 3
- Target Price
- FXNC $21.00
- CRDF $10.33
- AVG Volume (30 Days)
- FXNC 15.1K
- CRDF 1.0M
- Earning Date
- FXNC 02-11-2025
- CRDF 02-27-2025
- Dividend Yield
- FXNC 2.46%
- CRDF N/A
- EPS Growth
- FXNC N/A
- CRDF N/A
- EPS
- FXNC 1.12
- CRDF N/A
- Revenue
- FXNC $48,803,000.00
- CRDF $688,000.00
- Revenue This Year
- FXNC N/A
- CRDF $25.03
- Revenue Next Year
- FXNC $41.13
- CRDF N/A
- P/E Ratio
- FXNC $22.37
- CRDF N/A
- Revenue Growth
- FXNC N/A
- CRDF 49.57
- 52 Week Low
- FXNC $14.50
- CRDF $1.47
- 52 Week High
- FXNC $26.00
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- FXNC 72.96
- CRDF 60.32
- Support Level
- FXNC $24.89
- CRDF $3.78
- Resistance Level
- FXNC $25.44
- CRDF $4.23
- Average True Range (ATR)
- FXNC 0.46
- CRDF 0.22
- MACD
- FXNC 0.21
- CRDF 0.06
- Stochastic Oscillator
- FXNC 100.00
- CRDF 88.93
About FXNC First National Corporation
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. Loan products and services include personal loans, residential mortgages, home equity loans, and commercial loans. Deposit products and services include checking and savings. The Bank's wealth management division offers estate planning, investment management of assets, retirement accounts, and estate settlement.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").